Feasibility of an implementation intervention to increase attendance at diabetic retinopathy screening: protocol for a cluster randomised pilot trial.
Family practitioner
Feasibility
Implementation intervention
Pilot trial
Retinal screening
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
09
2019
accepted:
23
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Diabetic retinopathy screening (DRS) leads to the earlier detection of retinopathy and treatment that can prevent or delay the development of diabetes-related blindness. However, uptake continues to be sub-optimal in many countries, including Ireland. Routine management of type 2 diabetes largely takes place in primary care. As such, there may be an opportunity in primary care to introduce interventions to improve DRS uptake. However, few studies test the feasibility of interventions to enhance DRS uptake in this context. Our aim is to investigate the feasibility of an implementation intervention (IDEAs (Improving Diabetes Eye screening Attendance)) delivered in general practice to improve the uptake of the national DRS programme, RetinaScreen. The IDEAs study is a cluster randomised pilot trial with an embedded process evaluation and economic evaluation. Following stratification by practice size, eight general practices (clusters) will be randomly allocated to intervention ( Findings will determine whether IDEAsis feasible and acceptable and will be used to refine the intervention and study procedures. A definitive trial will determine whether IDEAs is a cost-effective intervention to improve DRS uptake and reduce diabetes-related blindness. ClinicalTrials.gov NCT03901898. Registered 3rd April 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic retinopathy screening (DRS) leads to the earlier detection of retinopathy and treatment that can prevent or delay the development of diabetes-related blindness. However, uptake continues to be sub-optimal in many countries, including Ireland. Routine management of type 2 diabetes largely takes place in primary care. As such, there may be an opportunity in primary care to introduce interventions to improve DRS uptake. However, few studies test the feasibility of interventions to enhance DRS uptake in this context. Our aim is to investigate the feasibility of an implementation intervention (IDEAs (Improving Diabetes Eye screening Attendance)) delivered in general practice to improve the uptake of the national DRS programme, RetinaScreen.
METHODS
METHODS
The IDEAs study is a cluster randomised pilot trial with an embedded process evaluation and economic evaluation. Following stratification by practice size, eight general practices (clusters) will be randomly allocated to intervention (
DISCUSSION
CONCLUSIONS
Findings will determine whether IDEAsis feasible and acceptable and will be used to refine the intervention and study procedures. A definitive trial will determine whether IDEAs is a cost-effective intervention to improve DRS uptake and reduce diabetes-related blindness.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03901898. Registered 3rd April 2019.
Identifiants
pubmed: 32426158
doi: 10.1186/s40814-020-00608-y
pii: 608
pmc: PMC7216495
doi:
Banques de données
ClinicalTrials.gov
['NCT03901898']
Types de publication
Journal Article
Langues
eng
Pagination
64Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Cochrane Database Syst Rev. 2015 Apr 29;(4):CD005470
pubmed: 25923419
J Gen Intern Med. 2018 Jan;33(1):72-78
pubmed: 29019046
Psychol Health. 2010 Dec;25(10):1229-45
pubmed: 20204937
Front Public Health. 2019 Jan 22;7:3
pubmed: 30723713
Diabet Med. 1998 Nov;15 Suppl 3:S38-43
pubmed: 9829768
Diabetes Care. 2004 Jan;27 Suppl 1:S84-7
pubmed: 14693935
Am J Prev Med. 2012 Jul;43(1):97-118
pubmed: 22704754
Syst Rev. 2016 Aug 11;5(1):134
pubmed: 27515938
BMJ Open. 2017 Feb 17;7(2):e013537
pubmed: 28213598
Health Educ Res. 2005 Jun;20(3):275-90
pubmed: 15632099
Diabetes Res Clin Pract. 2012 Apr;96(1):10-6
pubmed: 22137363
J Healthc Qual. 1999 Nov-Dec;21(6):35-8, 46
pubmed: 10662085
Cancer. 2007 Nov 1;110(9):2083-91
pubmed: 17893869
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):346-54
pubmed: 15006907
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Diabetes Metab Syndr. 2012 Oct-Dec;6(4):199-202
pubmed: 23199538
Eye (Lond). 2012 May;26(5):671-7
pubmed: 22302063
Diabetes Care. 2019 Jan;42(Suppl 1):S124-S138
pubmed: 30559237
Can J Ophthalmol. 2015 Apr;50(2):119-26
pubmed: 25863851
Implement Sci. 2014 Aug 06;9:87
pubmed: 25098587
Surv Ophthalmol. 2012 Jul-Aug;57(4):347-70
pubmed: 22542913
Ann Behav Med. 2018 Oct 22;52(11):941-951
pubmed: 30346495
J Epidemiol Community Health. 1997 Apr;51(2):187-91
pubmed: 9196650
Diabet Med. 2010 Mar;27(3):249-56
pubmed: 20536486
Ophthalmic Epidemiol. 2000 Sep;7(3):209-18
pubmed: 11035555
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Diabetes Care. 1997 Apr;20(4):520-3
pubmed: 9096973
Diabetologia. 2013 Oct;56(10):2187-93
pubmed: 23793717
Implement Sci. 2011 Sep 29;6:111
pubmed: 21958556
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
BMC Health Serv Res. 2017 Jan 7;17(1):16
pubmed: 28061856
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Am J Ophthalmol. 1999 Sep;128(3):324-30
pubmed: 10511027
J Med Screen. 2001;8(2):91-8
pubmed: 11480450
Adm Policy Ment Health. 2011 Jan;38(1):4-23
pubmed: 21197565
Br J Ophthalmol. 2015 Jan;99(1):64-8
pubmed: 25091950
Implement Sci. 2019 Jun 6;14(1):58
pubmed: 31171014
Implement Sci. 2012 Apr 24;7:38
pubmed: 22531013
Cochrane Database Syst Rev. 2001;(1):CD002943
pubmed: 11279781
Am J Prev Med. 2007 Oct;33(4):318-35
pubmed: 17888859
Diabet Med. 2010 Mar;27(3):282-8
pubmed: 20536490
Implement Sci. 2008 Mar 19;3:17
pubmed: 18353186
Acta Diabetol. 2017 Jun;54(6):515-525
pubmed: 28224275
Int J Qual Health Care. 2018 Apr 20;30(suppl_1):29-36
pubmed: 29447410
Retina. 2008 Feb;28(2):195-200
pubmed: 18301023
Br J Gen Pract. 2016 Feb;66(643):e114-27
pubmed: 26823263
J Med Screen. 2002;9(4):147-52
pubmed: 12518003
Health Technol Assess. 2018 May;22(29):1-160
pubmed: 29855423
Ophthalmology. 2006 Aug;113(8):1372-7
pubmed: 16769120
Nat Rev Endocrinol. 2011 Nov 08;8(4):228-36
pubmed: 22064493
Br J Ophthalmol. 2006 Mar;90(3):367-71
pubmed: 16488964
Am J Manag Care. 2010 Dec;16(12 Suppl HIT):SP72-81
pubmed: 21314226
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Evid Rep Technol Assess (Full Rep). 2010 Feb;(190):1-195, v
pubmed: 20726624
Implement Sci. 2013 Jun 10;8:65
pubmed: 23758995
Cancer Causes Control. 2006 Feb;17(1):45-52
pubmed: 16411052
Eur J Cancer Prev. 2018 May;27(3):227-236
pubmed: 28665812
Br J Cancer. 2011 Aug 9;105(4):475-80
pubmed: 21829202
Ophthalmology. 2003 Sep;110(9):1683-9
pubmed: 13129862
Isr Med Assoc J. 2002 Jun;4(6):424-5
pubmed: 12073414
Implement Sci. 2016 Mar 22;11:40
pubmed: 27001107
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
Lancet. 2012 Jun 16;379(9833):2252-61
pubmed: 22683130
Endoscopy. 2017 Jan;49(1):35-43
pubmed: 27997965
J Med Screen. 2008;15(1):1-4
pubmed: 18416946
Cochrane Database Syst Rev. 2018 Jan 15;1:CD012054
pubmed: 29333660
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
J Natl Cancer Inst Monogr. 2012 May;2012(44):34-41
pubmed: 22623594
J Behav Health Serv Res. 2017 Apr;44(2):177-194
pubmed: 26289563
Implement Sci. 2014 Dec 18;9:168
pubmed: 25518730
J Med Screen. 2006;13(3):152-5
pubmed: 17007657
Implement Sci. 2011 Sep 29;6:112
pubmed: 21958602
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259
pubmed: 22696318
J Med Screen. 2017 Sep;24(3):127-145
pubmed: 27754937
Qual Health Res. 2015 May;25(5):587-8
pubmed: 25829508
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Ann Fam Med. 2015 Nov;13(6):554-61
pubmed: 26553895
Br J Health Psychol. 2018 Sep;23(3):519-531
pubmed: 29453791